• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer
  • Best Managed Accounts
  • Forex Robots
  • Forex Brokers
  • Forex Signals
  • Social Trading Platforms
  • Community Reviews

  • Robots
  • Start Guide
  • Glossary
  • Basics
    • Currency Pairs
    • Charts
    • Candlesticks
    • Trading Tips
  • Strategies
    • Technical Analysis
    • Fundamental Analysis
    • Day Trading
    • Scalping
    • Swing Trading
    • Trend Following
  • News
  • Reviews
    • Forex Robots
    • Forex Brokers
  • Mustreads
  • Crypto Trading

Promising Results for Annovis Bio’s Phase 2/3 Study on Alzheimer’s Disease

October 12, 2023 by Forex Winner Leave a Comment

By Adam L. Cataldo

Annovis Bio, a clinical-stage drug platform company based in Berwyn, Pa., recently announced positive findings from an independent statistical group regarding its Phase 2/3 study on Alzheimer’s disease. The company revealed that there is no need to include additional patients, allowing the study to continue as planned.

Best Forex Robots ›

Compare leading trading systems on the market

Market Reaction and Future Outlook

Following this news, Annovis Bio’s shares experienced a significant boost, rising by 16% to $8.96 during midday trading on Thursday. However, despite this positive development, the stock still remains down by 33% this year.

Study Details

Annovis Bio’s study aims to enroll 320 patients with mild to moderate Alzheimer’s disease. Participants will be randomly assigned to receive varying doses of buntanetap or a placebo once per day. The company is focusing on evaluating the impact of buntanetap on cognition and activities of daily living—the two co-primary endpoints of the trial.

Pre-Planned Interim Analysis

The company has received the results of the pre-planned interim analysis, which included data from 107 patients across all cohorts after six weeks. This analysis confirmed that the trial should continue as planned and maintain its current size to maintain statistical power for both co-primary endpoints.

Key Endpoints of the Trial

The trial will assess the change from baseline to the end of treatment in two key factors: Alzheimer’s Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog11) and Alzheimer’s Disease Cooperative Study Clinician’s Global Impression of Change (ADCS-CGIC). These measures are vital in understanding the impact of the treatment on cognition and overall daily functioning.

In conclusion, Annovis Bio’s Phase 2/3 study has received promising news, allowing it to proceed as scheduled without the need for additional patients. These developments bring hope for advancements in the treatment of Alzheimer’s disease.

Best Forex Robots ›

Compare leading trading systems on the market

Filed Under: Forex News Tagged With: Alzheimer's disease, clinical study, Drug Development

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

Best Forex Robots

  1. Techberry 8.7
  2. Happy Forex 8.0
  3. Forex Fury 7.7
  4. Promax Gold EA 6.8
  5. Gump EA 6.4

Best Forex Brokers

  1. Techberry 8.7
  2. XM 8.2
  3. eToro 8.1
  4. Pepperstone 8.1
  5. IG 8.0

Latest News

Dogecoin (DOGE) Realized Profits Soar 225% in 24 Hours

May 22, 2025

AML Agency Tells Russians: Crypto Exchanges Send Us Your Data

May 21, 2025

Fresno car dealership owned by former MLB pitcher allowing Bitcoin as form of payment

May 20, 2025

Footer

Forex Broker Reviews

Saxo Bank

Saxo Bank Review

July 25, 2019 By Forex Winner

FBS

FBS Review

January 29, 2020 By Forex Winner

Charles Schwab

Charles Schwab Review

May 22, 2019 By Forex Winner

Forex Robot Reviews

Earn2Trade Review

August 20, 2023 By Shandor Brenner

FundedNext Review

August 16, 2023 By Shandor Brenner

Topstep Forex Review

August 14, 2023 By Shandor Brenner

EMAIL NEWSLETTER

Sign up to receive exclusive forex trading guides and insights from our team of experts!

Copyright © 2025 · Forex Traders Guide · About Us · Contact Us
Privacy Policy · Risk Disclosure